Cytek Biosciences Financials - Benzinga

Cytek Biosciences Inc

CTKBNASDAQ

Trade with Public

Trade with Public

$4.69

-0.20-4.09%

At close: Aug 14, 5:00 PM EST

$4.69

N/A

After Hours: Aug 14, 4:00 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Cytek Biosciences Financials

Cytek Biosciences (CTKB) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Cytek Biosciences Q2 EPS $(0.09), Inline, Sales $48.140M Miss $48.610M Estimate

Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 125 percent decrease over losses of $(0.04) per share from the same period last year.

Benzinga Newsdesk

PRO
Cytek Biosciences Raises FY2026 Sales Guidance from $205.000M-$212.000M to $207.000M-$212.000M vs $208.767M Est

Cytek Biosciences (NASDAQ:CTKB) raises FY2026 sales outlook from $205.000 million-$212.000 million to $207.000 million-$212.000 million vs $208.767 million estimate.

Benzinga Newsdesk

Concrete Pumping Holdings Reports Blowout Q2 Results, Joins ServiceTitan and Other Big Stocks Moving Higher in Friday's Pre-Market Session

US stock futures higher, Nasdaq futures down. Concrete Pumping Holdings shares up 28.94% pre-market. Other stocks moving in pre-market.

Avi Kapoor

PRO
Cytek Biosciences Affirms FY2026 Sales Guidance of $205.000M-$212.000M vs $208.235M Est

Cytek Biosciences (NASDAQ:CTKB) affirms FY2026 sales outlook from $205.000 million-$212.000 million to $205.000 million-$212.000 million vs $208.235 million estimate.

Benzinga Newsdesk

PRO
Cytek Biosciences Q1 EPS $(0.15) Misses $(0.10) Estimate, Sales $44.135M Miss $44.328M Estimate

Cytek Biosciences (NASDAQ:CTKB) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.10) by 50 percent. This is a 66.67 percent decrease over losses of $(0.09) per share from

Benzinga Newsdesk

PRO
Cytek Biosciences Sees FY2026 Sales $205.000M-$212.000M vs $207.058M Est

Cytek Biosciences (NASDAQ:CTKB) sees FY2026 sales of $205.000 million-$212.000 million vs $207.058 million analyst estimate.

Benzinga Newsdesk